FDA OKs new multiple sclerosis drug

WASHINGTON — The Food and Drug Administration said Wednesday it approved a new drug from Biogen Idec to control multiple sclerosis in adults with hard-to-treat forms of the disease.

The twice-a-day capsules, called Tecfidera, offer a new option for multiple sclerosis, a debilitating disease in which the body attacks its own nervous system. Cambridge, Mass.-based Biogen Idec already sells two other drugs for the disease, but both require injections.

There is no cure for multiple sclerosis and most patients experience relapses of symptoms, including loss of balance, weakness in arms and legs, and blurred vision. Over time patients usually become weaker and less coordinated. More than 2 million people worldwide have the disease, with about 400,000 of them in the U.S., according to Biogen.

The FDA said it approved Tecfidera based on two studies showing patients taking the drug had fewer relapses than patients taking a dummy pill.

The approval gives Biogen a new product in an increasingly crowded field of multiple sclerosis drugs.

The biotech drugmaker already sells the once-a-week multiple sclerosis injection Avonex. It also markets the once-a-month injection Tysabri through a partnership with Elan Corp. PLC of Ireland. However, Tysabri’s severe side effects have curtailed its use.

Tecfidera is designed to be taken orally, which could make it a preferred option for patients and doctors.

A Biogen executive said Wednesday that its three drugs would be used to treat different groups of patients.

“Multiple sclerosis is a reasonably complex disease and we think there are a lot of needs out there,” said Tony Kingsely, a vice president at Biogen. “By having three drugs out there I think we can address a lot of those needs.”

Kinglsey said the company will announce the pricing of the drug when it begins shipping in the next week.

Novartis launched the first pill-based multiple sclerosis drug, Gilenya, in March 2011. Sanofi won FDA approval for a second pill, its drug Aubagio, last September.

The top-selling drug for the disease worldwide is Copaxone, which is made by Teva Pharmaceutical Industries. That injection had sales of nearly $4 billion last year, according to Teva’s latest financial report.

Avonex and Tysabri had annual sales of $2.7 billion and $1.5 billion in 2011, the most recent year for which Biogen has reported annual sales.

Biogen Idec Inc. shares rose $5.59, or 3.2 percent, to close Wednesday at $182.68.

More in Local News

Former Monroe cop loses appeal on sex crimes conviction

Once a highly respected officer, he was found guilty of secretly videotaping his kids’ babysitter.

Derrick “Wiz” Crawford, 22, is a suspect in the homicide of his roommate. (Edmonds Police Department)
Roommate suspected in Edmonds killing found hiding in closet

Police had been searching for him for 10 days before locating him at a house in Everett.

Stormy weather knocks out power to parts of Everett

About 3,700 PUD customers lost electricity in Snohomish County early Thursday morning.

New leaders coming to county, state political parties

Hillary Moralez of Bothell takes over as chair for the Snohomish County Democratic Party.

Camano Island man gets 18 years for role in drug ring

He was convicted of helping lead a drug distribution network in four Washington counties.

Lake Stevens man missing since beginning of January

Jason Michael Knox White hasn’t used his credit card or withdrawn money from his bank since then.

Deal reached on water bill clears way for action on capital budget

“I think it addresses the issues of wells and water management in the state for the next 20 years.”

Young woman missing from Mukilteo found safe

She called her parents and told them she was at a museum in Seattle.

Navy to put filter in Coupeville’s contaminated water system

Chemicals from firefighting foam was found in the town’s drinking water.

Most Read